A plasma blood test that measures phosphorylated tau at the 217th position (P‑tau217) may offer a practical way to estimate an individual’s likelihood of developing cognitive impairment years before symptoms appear, according to findings presented in JAMA at the Alzheimer’s Association International Conference. The study reports that higher levels of P‑tau217 are linked to a greater risk of subsequent cognitive decline.
The analysis drew on six independent cohorts of cognitively unimpaired older adults, using longitudinal follow-up to evaluate how P‑tau217 relates to later impairment across multiple time horizons. Importantly, the association remained statistically significant even after adjusting for amyloid measured by PET imaging, suggesting the marker captures disease-relevant biology beyond amyloid status alone.
Because Alzheimer’s disease develops gradually, the ability to forecast risk over clinically meaningful windows could help clinicians and researchers target prevention efforts earlier. In this work, P‑tau217 functioned as a blood-based surrogate connected to amyloid and tau-related disease processes, reinforcing the view that tau pathology is not merely a late-stage phenomenon.
The authors argue that, if ongoing secondary prevention trials demonstrate that early intervention can delay or prevent cognitive decline, risk estimates derived from blood biomarkers like P‑tau217 could help identify which individuals are most likely to benefit. Such a strategy may also reduce reliance on resource-intensive procedures for large-scale screening.
However, the researchers emphasize that current risk projections are based on selected cohorts rather than broad population sampling. They also note that confidence is stronger for shorter projections than for longer ones, with estimates for 10 years generally more uncertain.
The modeling approach also faces important limitations, including incomplete accounting for vascular comorbidities and the competing risk of death, both of which can influence whether cognitive impairment is observed during follow-up. Additionally, P‑tau217 may not fully reflect non-Alzheimer contributors to cognitive impairment, including vascular effects and other neurodegenerative processes.
In parallel, the Alzheimer’s Association’s current clinical practice guidance cautions against testing cognitively unimpaired older adults outside research settings or clinical trials. While the results are promising for advancing prevention research, the clinical use of P‑tau217 is not yet endorsed.
The study’s publication DOI is 10.1001/jama.2026.12556. Media outlets can request interviews with contributing author Rachel F. Buckley, PhD, and corresponding author Reisa Sperling, MD, through the listed institutional media contacts.
Subject of Research: Alzheimer’s disease risk prediction using plasma biomarkers (P‑tau217)
Article Title: Not provided
News Publication Date: July 15, 2026
Web References: Not provided
References: doi:10.1001/jama.2026.12556
Image Credits: Not provided
Keywords: P‑tau217, plasma biomarker, Alzheimer’s disease, cognitive impairment, amyloid PET adjustment, tau pathology, prevention trials, older adults, risk modeling
